Phase I clinical trial of safety of L-serine for ALS patients
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We performed a randomized, double-blind phase I clinical trial for six months on the effects of oral L-serine in patients with ALS. The protocol called for enrollment of patients with a diagnosis of probable or definite ALS, age 18-85 years, disease duration of less than three years and forced vital capacity (FVC) ≥ 60%. Patients were randomly assigned to four different oral twice-daily dose regimens (0.5, 2.5, 7.5, or 15 g/dose). Blood, urine and CSF samples, ALS Functional Rating Scale-Revised (ALSFRS-R) scores and forced vital capacity (FVC) were obtained throughout the trial. Disease progression was compared with matched historical placebo controls from five previous ALS therapeutic trials. Of 20 patients enrolled, one withdrew before receiving study drug and two withdrew with gastro-intestinal problems. Three patients died during the trial. L-serine was generally well tolerated by the patients and L-serine did not appear to accelerate functional decline of patients as measured by slope of their ALSFRS-R scores. Based on this small study, L-serine appears to be generally safe for patients with ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936 · cited 1×
“Approximately 10% of patients have a familial history of the disease, and more than half of those patients carry a mutation of SOD1, TDP43, FUS, ANG, C9orf72 or other known genes (1,2).”
BackgroundCedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00210-5 · Cited by 3,307
Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease
Philips, T., & Robberecht, W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70015-1 · Cited by 646 · cited 1×
“Approximately 10% of patients have a familial history of the disease, and more than half of those patients carry a mutation of SOD1, TDP43, FUS, ANG, C9orf72 or other known genes (1,2).”
BackgroundCox, P. A., Davis, D. A., Mash, D. C., Metcalf, J. S., & Banack, S. A. (2016) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2015.2397 · Cited by 256
Self-citation
Cited by
Le Douce, J., Maugard, M., Veran, J., Matos, M., Jégo, P., Vigneron, P.-A., Faivre, E., Toussay, X., Vandenberghe, M., Balbastre, Y., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.004 · Cited by 328
The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial
Dalla Bella, E., Bersano, E., Antonini, G., Borghero, G., Capasso, M., Caponnetto, C., Chiò, A., Corbo, M., Filosto, M., Giannini, F., et al. (2021) · Brain · doi:10.1093/brain/awab167 · Cited by 59
L-serine treatment in patients with GRIN -related encephalopathy: a phase 2A, non-randomized study
Juliá-Palacios, N., Olivella, M., Sigatullina Bondarenko, M., Ibáñez-Micó, S., Muñoz-Cabello, B., Alonso-Luengo, O., Soto-Insuga, V., García-Navas, D., Cuesta-Herraiz, L., Andreo-Lillo, P., et al. (2024) · Brain · doi:10.1093/brain/awae041 · Cited by 36
Bradley, W. G., Miller, R. X., Levine, T. D., Stommel, E. W., & Cox, P. A. (2018) · Neurotoxicity Research · doi:10.1007/s12640-017-9741-x · Cited by 28
Self-citation
Metadata
- Authors
- Levine, T. D., Miller, R. G., Bradley, W. G., Moore, D. H., Saperstein, D. S., Flynn, L. E., Katz, J. S., Forshew, D. A., Metcalf, J. S., Banack, S. A., & Cox, P. A.
- Venue
- Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Publisher
- Informa UK Limited
- Published
- 2016-09-02
- Volume
- 18
- Issue
- 1-2
- Pages
- 107-111
- ISSN
- 2167-8421 (ISSN-L)
- 2167-9223
- OpenAlex
- W2509084766
- Cited by
- 82
- References
- 4
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I clinical trial of safety of L-serine for ALS patients. https://app.cochat.ai/papers/10.1080/21678421.2016.1221971
- The paper
- Levine, T. D., Miller, R. G., Bradley, W. G., Moore, D. H., Saperstein, D. S., Flynn, L. E., Katz, J. S., Forshew, D. A., Metcalf, J. S., Banack, S. A., & Cox, P. A. (2017). Phase I clinical trial of safety of L-serine for ALS patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. https://doi.org/10.1080/21678421.2016.1221971
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.